• US expands scope of Seattle Genetics’ Adcetris pharmatimes
    July 23, 2018
    US regulators have approved Seattle Genetics’ Adcetris in combination with chemotherapy for adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma.
PharmaSources Customer Service